NCT00702884View on ClinicalTrials.gov

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 17, 2013

Study Completion Date

December 30, 2013

Conditions
Esophageal Cancer
Interventions
DRUG

sunitinib malate

Sunitinib 37.5 mg daily for a 4 week cycle

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Tony Bekaii-Saab

OTHER